About Sutro Biopharma

At Sutro Biopharma we have pioneered a compelling and unique way of discovering, developing and manufacturing therapeutics. Our focus is aimed primarily on next generation cancer therapeutics and autoimmune disease — Antibody Conjugates, Bispecific Antibodies and cytokine derivatives. Unconstrained by traditional methods of cell-based discovery, we can design and develop targeted medicines by innovating outside the constraints of the cell.

Learn More

Technology

Our technology enables us to iteratively discover and test molecules in a rapid cycle of weeks rather than months, to rapidly identify the optimal molecule designed for safety and potency.

Learn More

Pipeline

Sutro Biopharma is working independently and with partners to develop novel cancer therapies, including antibody-drug conjugates, bispecific antibodies, and antibody-based therapeutics targeting immuno-oncology pathways.

Learn More

Recent News

14Nov

Sutro Biopharma Reports Third Quarter 2018 Financial Results

— STRO-001 Received Orphan Drug Designation for Treatment of Multiple Myeloma — STRO-002 to Begin Phase 1 Trial for Patients with Ovarian and.. Read More →
13Nov

Sutro Announces IND Submission and Conclusion of 30-Day Review Period for STRO-002, an Antibody-Drug Conjugate (ADC) Targeting Anti-Folate Receptor-α for Treatment of Ovarian and Endometrial Cancer

Initiation of Phase 1 Trial Planned for Early 2019 Company’s Second Cell-Free ADC Addressing Unmet Medical Need in Oncology    SOUTH SAN FRANCISCO,.. Read More →

Careers

At Sutro, collaboration drives how we achieve results. By putting the goals of the Company first, we aim to make a difference both as individuals and as part of a team.

Learn More